Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

T-cell lymphoblastic leukemia with t(11;22)(q24;q12) and EWSR1 rearrangement

Aleksandra Anna Łanocha, Barbara Zdziarska

Blood (2017) 129 (3): 393.

https://doi.org/10.1182/blood-2016-08-734897

Published: 2017

Journal Articles

Predictive and Prognostic Significance of Immunohistochemical Markers and Blood Absolute Lymphocyte Count in Diffuse Large B-Cell Lymphoma in Rituximab Era: A Polish Lymphoma Research Group (PLRG) Multicenter Retrospective Analysis

Anna Czyz, Monika Joks, Joanna E Drozd-Sokolowska, Wanda Knopinska-Posluszny, Magdalena Zawartko, Ewa Mizera-Nyczak, Dominik Dytfeld, Barbara Zdziarska, Wiktor-Wieslaw Jedrzejczak, Mieczyslaw Komarnicki

Blood (2014) 124 (21): 5413.

https://doi.org/10.1182/blood.V124.21.5413.5413

Published: 2014

Journal Articles

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5–2007 Study

Blood (2010) 116 (21): 2138.

https://doi.org/10.1182/blood.V116.21.2138.2138

Published: 2010

Journal Articles

Cladribine in Combination with Standard Daunorubicine and Cytarabine (DAC) as a Remission Induction Treatment Improves the Overall Survival in Untreated Adults with AML Aged < 60 y Contrary to Combination Including Fludarabine (DAF): A Multicenter, Randomized, Phase III PALG AML 1/2004 DAC/DAF/DA Study in 673 Patients-A Final Update.

Blood (2009) 114 (22): 2055.

https://doi.org/10.1182/blood.V114.22.2055.2055

Published: 2009

Journal Articles

Addition of Cladribine to the Standard Daunorubicine - Cytarabine (DA 3+7) Remission Induction Protocol (DAC) Contrary to Adjunct of Fludarabine (DAF) Improves the Overall Survival in Untreated Adults with Acute Myeloid Leukemia Aged up to 60 Y: A Multicenter, Randomized, Phase III PALG AML 1/2004 DAF/DAC/DA Study in 673 Patients

Blood (2008) 112 (11): 133.

https://doi.org/10.1182/blood.V112.11.133.133

Published: 2008

Journal Articles

90 Y-Zevalin® ( 90 Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation in Mantle Cell Lymphoma (MCL) Patients, Not Illegible for Intensive Therapy Protocols.

Wojciech Jurczak, Agnieszka Giza, Dagmara Zimowska-Curylo, Alicja Hubalewska-Dydejczyk, Anna Sowa-Staszczak, Wanda Knopinska-Posluszny, Andrzej Hellmann, Barbara Zdziarska, Tomasz Wrobel, Slawomira Krycz-Krzemien, Lidia Poplawska, Jan Walewski, Aleksander B. Skotnicki

Blood (2007) 110 (11): 4497.

https://doi.org/10.1182/blood.V110.11.4497.4497

Published: 2007

Journal Articles

Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial

Blood (2007) 109 (9): 3672–3675.

https://doi.org/10.1182/blood-2006-08-042929

Published: 2007

Journal Articles

Cladribine in Weekly Versus Daily Schedule for Untreated Active Hairy Cell Leukemia: Final Report of Polish Adult Leukemia Group (PALG) Prospective, Randomized, Multicenter Trial.

Blood (2006) 108 (11): 2485.

https://doi.org/10.1182/blood.V108.11.2485.2485

Published: 2006

Journal Articles

Daunorubicin, Cytarabine and Fludarabine (DAF) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Phase II Study by the Polish Adult Leukemia Group (PALG).

Jerzy Holowiecki, Sebastian Grosicki, MD, Slawomira Krzemien, MD, Aleksander Skotnicki, Krzysztof Warzecha, Barbara Zdziarska, MD, Beata Stella-Holowiecka, MD, Malgorzata Krawczyk-Kulis, MD, Malgorzata Kopera, MD, Maria Wojciechowska, MD

Blood (2004) 104 (11): 4507.

https://doi.org/10.1182/blood.V104.11.4507.4507

Published: 2004

Journal Articles

The Effect of Subsequent Therapies in the Patients with Chronic Lymphocytic Leukemia Previously Treated with Cladribine and Prednisone or Chlorambucil and Prednisone in Randomized Studies.

Tadeusz Robak, Jerzy Z. Blonski, Marek Kasznicki, Joanna Gora-Tybor, Anna Dmoszynska, Maria Wojtaszko, Aleksander Skotnicki, Wieslaw Nowak, Andrzej Hellmann, Krzysztof Lewandowski, Barbara Zdziarska, Lech Konopka, Bernadeta Ceglarek, Jadwiga Dwilewicz-Trojaczek, Piotr Boguradzki, Kazimierz Kuliczkowski, Kazimierz Sulek, Krzysztof Warzocha

Blood (2004) 104 (11): 4819.

https://doi.org/10.1182/blood.V104.11.4819.4819

Published: 2004

Journal Articles

Randomized Comparison of Weekly Administration and Daily Courses of Cladribine in Patients with Hairy Cell Leukemia - Updated Results.

Tadeusz Robak, Marek Kasznicki, Joanna Gora-Tybor, Jadwiga Dwilewicz-Trojaczek, Anna Dmoszynska, Maria Wojtaszko, Barbara Zdziarska, Malgorzata Calbecka, Andrzej Hellmann, Beata Stella-Holowiecka, Kazimierz Sulek, Aleksander Skotnicki, Krystyna Zawilska, Janusz Kloczko, Krzysztof Warzocha, Lech Konopka

Blood (2004) 104 (11): 3478.

https://doi.org/10.1182/blood.V104.11.3478.3478

Published: 2004

Journal Articles

Addition of Cladribine to the Standard AML Treatment Improves Long-Term Outcome in High Tumor Burden and Older Than 40 Years Acute Myeloid Leukemia Patients. Five-Year Follow-Up of the Polish Adult Leukemia Group (PALG 1999 DAC vs. DA Study).

Jerzy Holowiecki, Sebastian Grosicki, MD, Tadeusz Robak, Slawomira Krzemien, MD, Sebastian Giebel, MD, Andrzej Hellmann, Aleksander Skotnicki, Wieslaw W. Jedrzejczak, Lech Konopka, Kazimierz Kuliczkowski, Barbara Zdziarska, MD, Anna Dmoszynska

Blood (2004) 104 (11): 1795.

https://doi.org/10.1182/blood.V104.11.1795.1795

Published: 2004

Journal Articles

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial

Tadeusz Robak, Jerzy Z. Bloński, Marek Kasznicki, Maria Blasińska-Morawiec, Euzebiusz Krykowski, Anna Dmoszyńska, Halina Mrugala-Śpiewak, Aleksander B. Skotnicki, Wieslaw Nowak, Lech Konopka, Bernadeta Ceglarek, Stanislaw Maj, Jadwiga Dwilewicz-Trojaczek, Andrzej Hellmann, Ignacy Urasiński, Barbara Zdziarska, Sabina Kotlarek-Haus, Stanislaw Potoczek, Pawel Grieb

Blood (2000) 96 (8): 2723–2729.

https://doi.org/10.1182/blood.V96.8.2723

Published: 2000

NARROW

T-cell lymphoblastic leukemia with t(11;22)(q24;q12) and EWSR1 rearrangement

Predictive and Prognostic Significance of Immunohistochemical Markers and Blood Absolute Lymphocyte Count in Diffuse Large B-Cell Lymphoma in Rituximab Era: A Polish Lymphoma Research Group (PLRG) Multicenter Retrospective Analysis

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5–2007 Study

90 Y-Zevalin® ( 90 Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation in Mantle Cell Lymphoma (MCL) Patients, Not Illegible for Intensive Therapy Protocols.

Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial

Cladribine in Weekly Versus Daily Schedule for Untreated Active Hairy Cell Leukemia: Final Report of Polish Adult Leukemia Group (PALG) Prospective, Randomized, Multicenter Trial.

Daunorubicin, Cytarabine and Fludarabine (DAF) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Phase II Study by the Polish Adult Leukemia Group (PALG).

The Effect of Subsequent Therapies in the Patients with Chronic Lymphocytic Leukemia Previously Treated with Cladribine and Prednisone or Chlorambucil and Prednisone in Randomized Studies.

Randomized Comparison of Weekly Administration and Daily Courses of Cladribine in Patients with Hairy Cell Leukemia - Updated Results.

Addition of Cladribine to the Standard AML Treatment Improves Long-Term Outcome in High Tumor Burden and Older Than 40 Years Acute Myeloid Leukemia Patients. Five-Year Follow-Up of the Polish Adult Leukemia Group (PALG 1999 DAC vs. DA Study).

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only